Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac. With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies. The company’s oncology strategy focuses on… Read More
Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine. CureVac has filed the lawsuit in the German Regional Court in… Read More
CureVac has announced results of the second interim analysis of its international pivotal Phase IIb/III study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation Covid-19 vaccine candidate, CVnCoV. At second interim analysis, statistical success criteria were not met. In the unprecedented context of at least 13 variants circulating… Read More
